Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Chimeric univalent antibodies for treating lymphoid malignancies.

G T Stevenson, V M Cole, J Summerton

Medical Oncology and Tumor Pharmacotherapy

|January 1, 1984

Summary

New antibody derivatives enhance cancer treatment by increasing cytotoxic potential. These chimeric univalent antibodies (FabIgG, FabFc) effectively recruit immune cells for targeted cancer cell killing.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Diagnostic accuracy of ultrasensitive heat-denatured HIV-1 p24 antigen in non-B subtypes in Kampala, Uganda.

International journal of STD & AIDS·2011

Same author

Engineered antibody for treating lymphoma.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2002

Same author

Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs.

Nucleic acids research·2001

Same author

Thioether-bonded constructs of Fab'gamma and Fc gamma modules utilizing differential reduction of interchain disulfide bonds.

Journal of immunology (Baltimore, Md. : 1950)·2001

Same author

Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients.

Proceedings of the National Academy of Sciences of the United States of America·2000

Same author

Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc.

Antisense & nucleic acid drug development·2000

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Antibody-based cancer therapies require enhanced cytotoxic potential for greater efficacy.
Univalent antibody derivatives with intact Fc-regions can avoid antigenic modulation and recruit cytotoxic effectors like complement.
Previous work demonstrated the potential of anti-idiotype antibodies against neoplastic lymphocytes.

Purpose of the Study:

To develop and evaluate chimeric univalent antibody derivatives for improved cancer immunotherapy.
To assess the ability of these derivatives to recruit cytotoxic effector functions.
To determine if these derivatives are minimally immunogenic and efficient recruiters of host effector functions.

Main Methods:

Fab' gamma fragments from antibodies were linked via thioether bonds to half-cystine in normal immunoglobulins.
Two derivatives, FabIgG and FabFc, were created, utilizing IgG and Fc gamma as effector partners, respectively.
The derivatives' ability to invoke complement and K-cell killing of target lymphocytes was evaluated.

Main Results:

The chimeric univalent antibody derivatives (FabIgG and FabFc) demonstrated superior ability to invoke complement and K-cell killing compared to the parent antibody.
These derivatives showed promise for being minimally immunogenic.
The homologous Fc region in the derivatives is expected to efficiently recruit host effector functions.

Conclusions:

Chimeric univalent antibodies represent a promising advancement in cancer immunotherapy.
These derivatives offer enhanced cytotoxic potential and effective recruitment of immune effector functions.
The minimally immunogenic nature and efficient effector recruitment suggest a favorable profile for clinical application in cancer treatment.

Related Experiment Videos